Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell Leukemia

Inclusion Criteria:

1. Patients or their legal guardians voluntarily participate and sign the informedconsent;
2. Male or female patients aged 18-70 years (including 18 and 70 years);
3. The patient was diagnosed as NK/T cell lymphoma /NK cell leukemia by pathology or flowcytometry, and currently has no effective treatment options, such as relapse afterchemotherapy or hematopoietic stem cell transplantation; Alternatively, patientsvoluntarily choose to administer anti-CD56-CAR T cells as salvage therapy.
4. The following two categories are included:(1)NK/T cell lymphoma;(2) NK cell leukemia.
5. Subject:

(1)There was no remission or residual lesions after treatment, and HSCT (auto/allo-HSCT)was not suitable; (2)Relapse occurred after CR, and HSCT (auto/allo-HSCT) was not suitable; (3)Patients with high risk factors; (4)Relapse or no remission after hematopoietic stemcell transplantation or cellular immunotherapy. 6. Measurable or evaluable lesions; 7. The patient's main tissues and organs function well:

1. Liver function: ALT/AST < 3 times the upper limit of normal (ULN) and total bilirubin ≤34.2μmol/L;
2. Renal function: creatinine < 220 μmol/L;
3. Lung function: indoor oxygen saturation ≥95%;
4. Cardiac function: left ventricular ejection fraction (LVEF) ≥40%.
5. The patients had not received any anti-cancer treatment such as chemotherapy,radiotherapy, immunotherapy (such as immunosuppressive drugs) within the first 4 weeks ofenrollment, and their previous treatment-related toxic reactions had recovered to ≤ grade 1at the time of enrollment (except low toxicity such as hair loss);
6. The patient's peripheral shallow venous blood flow is smooth, which can meet the needsof intravenous infusion;
7. Patients with ECOG score ≤2 and expected survival time ≥3 months.

Exclusion Criteria:

1. Women who are pregnant (urine/blood pregnancy test positive) or breastfeeding;
2. Men or women who have planned to become pregnant within the last 1 year;
3. The patients were not guaranteed to take effective contraceptive measures (condoms orcontraceptives, etc.) within 1 year after enrollment;
4. Patients had uncontrollable infectious diseases within 4 weeks prior to enrollment;
5. Active hepatitis B/C virus;
6. HIV-infected patients;
7. Suffering from a serious autoimmune disease or immunodeficiency disease;
8. The patient is allergic to antibodies, cytokines and other macromolecular biologicaldrugs;
9. The patient had participated in other clinical trials within 6 weeks prior toenrollment;
10. Systemic use of hormones within 4 weeks prior to enrollment (except for inhaledhormones);
11. Suffers from mental illness;
12. The patient has substance abuse/addiction;
13. According to the researchers' judgment, the patient had other conditions that were notsuitable for inclusion.